Literature DB >> 11716123

Influence of human T-cell lymphocytotropic virus type 1 infection on serologic and skin tests for strongyloidiasis.

A F Porto1, J Oliveira Filho, F A Neva, G Orge, L Alcântara, A Gam, E M Carvalho.   

Abstract

The aim of this study was to determine whether human T-cell lymphocytotropic virus type 1 (HTLV-1) infection may affect the levels of parasite-specific immunoglobulin (Ig) G and IgE and the positivity of the skin test for strongyloidiasis. Participants included 67 patients with strongyloidiasis (40 without HTLV-1 infection and 27 coinfected with HTLV-1). We determined IgG and IgE levels by enzyme-linked immunosorbent assay, and the immediate hypersensitivity skin test was performed with the metabolic Strongyloides stercoralis antigen. Specific IgE levels and the size of skin reactions in patients without HTLV-1 were higher (P < 0.01) than those observed in patients coinfected with HTLV-1. Additionally, 89% of patients without HTLV-1 had specific IgE and 92.5% had positive skin tests; however, these values were significantly reduced (P < 0.01) in patients coinfected with HTLV-1 (44% and 59%, respectively). These data show that HTLV-1 infection decreases the sensitivity of detection of S. stercoralis-specific IgE, the size of the immediate hypersensitivity reaction, and the sensitivity of these tests in the diagnosis of strongyloidiasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11716123     DOI: 10.4269/ajtmh.2001.65.610

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  8 in total

1.  Strongyloides stercoralis hyperinfection presenting as subacute small bowel obstruction following immunosuppressive chemotherapy for multiple myeloma.

Authors:  Adrian Matthew Shields; Rashida Goderya; Mustafa Atta; Prakash Sinha
Journal:  BMJ Case Rep       Date:  2014-01-27

2.  HTLV-1 modifies the clinical and immunological response to schistosomiasis.

Authors:  A F Porto; S B Santos; L Alcantara; J B Guerreiro; J Passos; T Gonzalez; F Neva; D Gonzalez; J L Ho; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

Review 3.  Strongyloides stercoralis in the Immunocompromised Population.

Authors:  Paul B Keiser; Thomas B Nutman
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

4.  Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1.

Authors:  M Satoh; S Kiyuna; Y Shiroma; H Toma; A Kokaze; Y Sato
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 5.  The laboratory diagnosis and follow up of strongyloidiasis: a systematic review.

Authors:  Ana Requena-Méndez; Peter Chiodini; Zeno Bisoffi; Dora Buonfrate; Eduardo Gotuzzo; José Muñoz
Journal:  PLoS Negl Trop Dis       Date:  2013-01-17

6.  Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.

Authors:  A A Cruz; F Lima; E Sarinho; G Ayre; C Martin; H Fox; P J Cooper
Journal:  Clin Exp Allergy       Date:  2007-02       Impact factor: 5.018

7.  Persistent strongyloidiasis complicated by recurrent meningitis in an HTLV seropositive Peruvian migrant resettled in Italy.

Authors:  Lorenzo Zammarchi; Francesca Montagnani; Giacinta Tordini; Eduardo Gotuzzo; Zeno Bisoffi; Alessandro Bartoloni; Andrea De Luca
Journal:  Am J Trop Med Hyg       Date:  2015-04-06       Impact factor: 2.345

8.  CATMAT statement on disseminated strongyloidiasis: Prevention, assessment and management guidelines.

Authors:  A K Boggild; M Libman; C Greenaway; A E McCarthy
Journal:  Can Commun Dis Rep       Date:  2016-01-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.